| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $49,000 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Lo Steven | President, Chief Exec Officer | 1 | $49,000 | 0 | $0 | $49,000 |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Vaxart, Inc. have bought $49,000 and sold $0 worth of Vaxart, Inc. stock.
On average, over the past 5 years, insiders at Vaxart, Inc. have bought $23,455 and sold $2.53M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lo Steven (President, Chief Exec Officer) — $49,000.
The last purchase of 100,000 shares for transaction amount of $49,000 was made by Lo Steven (President, Chief Exec Officer) on 2025‑05‑19.
| 2025-05-19 | Lo Steven | President, Chief Exec Officer | 100,000 0.043% | $0.49 | $49,000 | -9.96% | ||
| 2024-06-18 | Watson W. Mark | director | 20,000 0.01% | $0.68 | $13,578 | -2.56% | ||
| 2022-12-28 | Watson W. Mark | director | 20,000 0.0152% | $0.76 | $15,140 | -1.28% | ||
| 2022-06-22 | Ahmad Fuad | Interim CFO | 5,000 0.0037% | $3.22 | $16,100 | -64.14% | ||
| 2022-01-10 | Sale | Yedid Robert A. | director | 1,500 0.0012% | $6.01 | $9,015 | -42.60% | |
| 2021-11-30 | Sale | Echerd Margaret | SVP, Principal Accntng Officer | 3,602 0.003% | $8.00 | $28,816 | -52.20% | |
| 2021-09-10 | Sale | Echerd Margaret | SVP, Principal Accntng Officer | 1,801 0.0015% | $9.10 | $16,389 | -45.32% | |
| 2021-08-10 | Sale | Tucker Sean | SVP, Chief Scientific Officer | 10,000 0.0089% | $10.20 | $102,000 | -45.30% | |
| 2021-08-10 | Sale | Echerd Margaret | SVP, Principal Accntng Officer | 1,801 0.0016% | $10.00 | $18,010 | -45.30% | |
| 2021-07-19 | Sale | Echerd Margaret | SVP, Principal Accntng Officer | 1,800 0.0015% | $8.00 | $14,400 | -29.40% | |
| 2021-06-11 | Sale | Yedid Robert A. | director | 10,000 0.0081% | $8.61 | $86,109 | -24.14% | |
| 2021-06-11 | Sale | Echerd Margaret | SVP, Principal Accntng Officer | 1,802 0.0014% | $8.00 | $14,416 | -24.14% | |
| 2021-06-09 | Sale | Echerd Margaret | SVP, Principal Accntng Officer | 47,555 0.0412% | $8.00 | $380,440 | -12.70% | |
| 2021-05-07 | Sale | Latour Wouter | director | 100,000 0.0819% | $7.13 | $712,750 | -6.18% | |
| 2021-05-06 | Sale | Latour Wouter | director | 100,000 0.078% | $6.54 | $653,890 | -2.45% | |
| 2021-03-04 | Sale | Latour Wouter | director | 150,000 0.1327% | $6.04 | $906,450 | +16.22% | |
| 2020-11-23 | Sale | Latour Wouter | director | 333,334 0.2702% | $6.32 | $2.11M | +1.05% | |
| 2020-06-29 | Sale | ARMISTICE CAPITAL, LLC | director | 9.39M 13.9107% | $8.29 | $77.8M | -6.34% | |
| 2020-06-26 | Sale | ARMISTICE CAPITAL, LLC | director | 18.23M 31.5118% | $10.38 | $189.19M | -12.81% | |
| 2020-06-03 | Sale | ARMISTICE CAPITAL, LLC | director | 400,000 0.5415% | $2.77 | $1.11M | +150.91% |
| Lo Steven | President, Chief Exec Officer | 100000 0.0438% | $44,000.00 | 1 | 0 | |
| Third Point LLC | other | 6890000 3.0178% | $3.03M | 4 | 1 | <0.0001% |
| Finney Michael J. | director | 452572 0.1982% | $199,131.68 | 3 | 0 | <0.0001% |
| FAHIM RAAFAT E F | President, CEO and CFO | 373474 0.1636% | $164,328.53 | 3 | 3 | +50% |
| ARMISTICE CAPITAL, LLC | director | 145523 0.0637% | $64,030.12 | 9 | 24 | +502.07% |
| Aryeh Jason | director | 131783 0.0577% | $57,984.52 | 0 | 37 | |
| PLUMB RUSSELL H | CEO & President | 127579 0.0559% | $56,134.76 | 2 | 0 | <0.0001% |
| PATTI JOSEPH M | CEO | 126128 0.0552% | $55,496.32 | 6 | 0 | <0.0001% |
| Davis Todd C | director | 120000 0.0526% | $52,800.00 | 0 | 1 | |
| GURY DAVID J | director | 106400 0.0466% | $46,816.00 | 0 | 11 | |
| Kessler Paul D. | SVP Clinical, Med. & Reg.; CMO | 105128 0.046% | $46,256.32 | 0 | 9 | |
| Fox James | director | 100614 0.0441% | $44,270.16 | 2 | 0 | <0.0001% |
| Watson W. Mark | director | 78125 0.0342% | $34,375.00 | 2 | 0 | <0.0001% |
| KNOTT DAVID M | 10 percent owner | 69900 0.0306% | $30,756.00 | 1 | 2 | <0.0001% |
| Hudson Leslie | director | 55759 0.0244% | $24,533.96 | 0 | 1 | |
| Tucker Sean | SVP, Chief Scientific Officer | 43881 0.0192% | $19,307.64 | 1 | 1 | <0.0001% |
| Kalnik Matthew W. | SVP Strategic Plan. & Bus. Ops | 41050 0.018% | $18,062.00 | 0 | 10 | |
| VANLENT ANNE | director | 35000 0.0153% | $15,400.00 | 1 | 0 | <0.0001% |
| COX GEOFFREY F | director | 25679 0.0112% | $11,298.76 | 2 | 0 | +74.82% |
| Richard John P | director | 20000 0.0088% | $8,800.00 | 1 | 0 | +568.57% |
| Siegel Jordan I | Sr. VP Fin. & Admin, CFO Treas | 18157 0.008% | $7,989.16 | 0 | 2 | |
| DAVIS PETER B | director | 14630 0.0064% | $6,437.20 | 2 | 0 | +7.57% |
| EBRIGHT GEORGE W | director | 12325 0.0054% | $5,423.00 | 0 | 2 | |
| Jooste H Le Roux | Sr. VP, Glbl. Sales & Mktng. | 10000 0.0044% | $4,400.00 | 1 | 0 | +54.12% |
| NASO ROBERT B | Sr. VP Qual., Reg., Prod. Dev. | 9734 0.0043% | $4,282.91 | 0 | 1 | |
| COLONNESE MARK P | Chief Financial Officer | 7000 0.0031% | $3,080.00 | 1 | 0 | +9.38% |
| Ahmad Fuad | Interim CFO | 5000 0.0022% | $2,200.00 | 1 | 0 | <0.0001% |
| MCLAIN THOMAS H | Chairman, CEO and President | 240 0.0001% | $105.60 | 1 | 0 | +35.44% |
| LYNCH TIMOTHY P | director | 0 0% | $0 | 0 | 1 | |
| Echerd Margaret | SVP, Principal Accntng Officer | 0 0% | $0 | 0 | 6 | |
| Latour Wouter | director | 0 0% | $0 | 1 | 4 | +452.78% |
| Yedid Robert A. | director | 0 0% | $0 | 0 | 2 |
$30,470,407 | 140 | 20.39% | $106.76M | |
$49,091,668 | 110 | 13.11% | $104.01M | |
Vaxart, Inc. (VXRT) | $16,259,194 | 41 | 120.51% | $100.46M |
$909,129 | 37 | 42.19% | $110.75M | |
$64,487,106 | 32 | -22.92% | $91.47M | |
$36,079,815 | 31 | 43.23% | $92.37M | |
$26,678,853 | 21 | -5.95% | $102.99M | |
$38,821,584 | 20 | -2.17% | $93.37M | |
$33,027,560 | 17 | -10.02% | $105.49M | |
$277,862 | 15 | 59.79% | $93.18M | |
$18,535,159 | 14 | 57.32% | $93.42M | |
$145,194 | 11 | -27.37% | $108.75M | |
$135,589,307 | 10 | 32.46% | $101.45M | |
$99,355,998 | 7 | -65.74% | $90.86M | |
$272,982 | 6 | -28.53% | $92.96M | |
$401,951 | 4 | 57.41% | $90.85M | |
$30,149,552 | 3 | -66.74% | $103.29M | |
$16,003,671 | 3 | 55.38% | $102.11M | |
$3,620 | 1 | 94.16% | $97.17M |
| Increased Positions | 26 | +21.49% | 1M | +3.88% |
| Decreased Positions | 40 | -33.06% | 10M | -27.41% |
| New Positions | 10 | New | 320,737 | New |
| Sold Out Positions | 14 | Sold Out | 719,171 | Sold Out |
| Total Postitions | 107 | -11.57% | 27M | -23.54% |
| Sio Capital Management, Llc | $5,182.00 | 5.05% | 11.52M | -2M | -15.38% | 2024-12-31 |
| Vanguard Group Inc | $4,535.00 | 4.42% | 10.08M | 0 | 0% | 2024-12-31 |
| Millennium Management Llc | $1,346.00 | 1.31% | 2.99M | -978,449 | -24.65% | 2024-12-31 |
| Geode Capital Management, Llc | $1,171.00 | 1.14% | 2.6M | +57,911 | +2.28% | 2024-12-31 |
| Blackrock, Inc. | $803.00 | 0.78% | 1.78M | -215,555 | -10.78% | 2025-03-31 |
| Silverarc Capital Management, Llc | $485.00 | 0.47% | 1.08M | +77,782 | +7.78% | 2024-12-31 |
| State Street Corp | $310.00 | 0.3% | 688,845 | +94,700 | +15.94% | 2024-12-31 |
| Squarepoint Ops Llc | $233.00 | 0.23% | 516,798 | +251,789 | +95.01% | 2024-12-31 |
| Citadel Advisors Llc | $226.00 | 0.22% | 501,623 | +501,623 | New | 2024-12-31 |
| Ubs Group Ag | $223.00 | 0.22% | 495,793 | +495,475 | +155,809.75% | 2024-12-31 |